Eurosurv. Effectiveness of influenza vaccines in children aged 6 to 59 months: a test-negative case–control study at primary care and hospital level,

[tetano]

• Gloria Pérez-Gimeno[SUP]1,2[/SUP] , Clara Mazagatos[SUP]1,2[/SUP] , Nicola Lorusso[SUP]3[/SUP] , Luca Basile[SUP]4[/SUP] , Isabel Martínez-Pino[SUP]2,5[/SUP] , Francisca Corpas Burgos[SUP]6[/SUP] , Noa Batalla Rebolla[SUP]7[/SUP] , Mercedes B Rumayor Zarzuelo[SUP]8[/SUP] , Blanca Andreu Ivorra[SUP]9[/SUP] , Jaume Giménez Duran[SUP]10[/SUP] , Daniel Castrillejo[SUP]11[/SUP] , Inés Guiu Cañete[SUP]12[/SUP] , Marta Huerta Huerta[SUP]13[/SUP] , Marta García Becerril[SUP]14[/SUP] , Violeta Ramos Marín[SUP]15[/SUP] , Inmaculada Casas[SUP]2,16[/SUP] , Francisco Pozo[SUP]2,16[/SUP] , Susana Monge[SUP]1,17[/SUP] , the SiVIRA group[SUP]18[/SUP]

During 2023/24, all children aged 6 to 59 months were targeted for seasonal influenza vaccination in Spain nationally. Using a test-negative case–control design with sentinel surveillance data, we estimated adjusted influenza vaccine effectiveness (IVE) against any influenza type to be 70% (95% confidence interval (CI): 51 to 81%) for primary care patients with acute respiratory illness (ARI) and 77% (95% CI: 21 to 93%) for hospitalised patients with severe ARI. In primary care, where most subtyped viruses (61%; 145/237) were A(H1N1), adjusted IVE was 77% (95% CI: 56 to 88%) against A(H1N1)pdm09.
​

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.40.2400618#html_fulltext